BioSpace3h
Kezar’s Autoimmune Drug Hit With Second FDA Clinical Hold in as Many Months
Following patient deaths in a lupus trial that led to the termination of that program, Kezar’s autoimmune candidate ...
BioSpace4h
5 Reasons Biogen’s Shares Have Dropped 36% in 2024
A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...
BioSpace19h
Fledgling Obesity Biotech Metsera Raises Another $215M for Long-Acting GLP-1
Despite crowding in the next-gen weight loss space, Metsera has raised over $500 million since its April launch, indicating a ...
BioSpace13hOpinion
Opinion: Don’t Import Bad Policy Ideas on Drug Pricing
Suggestions that the U.S. should emulate other countries on drug price controls or patents obscure how our present policies ...
BioSpace19h
Amgen Suffers Surprise Blow as New Bone Density Safety Concerns for MariTide Surface
Cantor Fitzgerald analyst Olivia Brayer found supplementary bone marrow density data for Amgen’s obesity candidate MariTide ...
BioSpace19h
AbbVie’s Surprise Schizophrenia Flop, AstraZeneca’s China Drama, Hope in Huntington’s, More
Possibly the biggest news this week comes from the schizophrenia space, where AbbVie’s emraclidine failed two mid-stage ...
BioSpace19h
Syros Crashes Over 90% on Late-Stage MDS Fail, Loan Default
With the Phase III failure, Syros will discontinue the study of tamibarotene for myelodysplastic syndrome and will default on its loan from Oxford Finance LLC. Syros Pharmaceuticals on Tuesday ...